Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next
Recursion Pharmaceuticals shares surged 11% on Dec. 17 after JPMorgan upgraded the stock, then retreated to close at $4.26 on Dec. 19 as trading volume spiked. The moves followed positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis, showing a median 43% reduction in polyp burden at 13 weeks. Most adverse events were mild or moderate.